EA026375B1 - Антигенсвязывающие белки, специфические в отношении сывороточного амилоидного компонента р - Google Patents

Антигенсвязывающие белки, специфические в отношении сывороточного амилоидного компонента р Download PDF

Info

Publication number
EA026375B1
EA026375B1 EA201290671A EA201290671A EA026375B1 EA 026375 B1 EA026375 B1 EA 026375B1 EA 201290671 A EA201290671 A EA 201290671A EA 201290671 A EA201290671 A EA 201290671A EA 026375 B1 EA026375 B1 EA 026375B1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibody
human
δαρ
antigen binding
δεο
Prior art date
Application number
EA201290671A
Other languages
English (en)
Russian (ru)
Other versions
EA201290671A1 (ru
Inventor
Теджиндер Каур Бхиндер
Сюзанна Карен Форд
Фолькер Гермашевски
Алан Питер Льюис
Марк Брайан Пепис
Original Assignee
Глаксо Груп Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43881068&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA026375(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Глаксо Груп Лимитед filed Critical Глаксо Груп Лимитед
Publication of EA201290671A1 publication Critical patent/EA201290671A1/ru
Publication of EA026375B1 publication Critical patent/EA026375B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EA201290671A 2010-03-03 2011-03-01 Антигенсвязывающие белки, специфические в отношении сывороточного амилоидного компонента р EA026375B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30995710P 2010-03-03 2010-03-03
PCT/EP2011/053038 WO2011107480A1 (en) 2010-03-03 2011-03-01 Antigen binding proteins specific for serum amyloid p component

Publications (2)

Publication Number Publication Date
EA201290671A1 EA201290671A1 (ru) 2013-05-30
EA026375B1 true EA026375B1 (ru) 2017-04-28

Family

ID=43881068

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201290671A EA026375B1 (ru) 2010-03-03 2011-03-01 Антигенсвязывающие белки, специфические в отношении сывороточного амилоидного компонента р

Country Status (39)

Country Link
EP (2) EP2542261B1 (OSRAM)
JP (2) JP5922592B2 (OSRAM)
KR (1) KR101817265B1 (OSRAM)
CN (1) CN102858371B (OSRAM)
AR (1) AR080432A1 (OSRAM)
AU (1) AU2011223048C1 (OSRAM)
BR (1) BR112012021926A2 (OSRAM)
CA (1) CA2789557A1 (OSRAM)
CL (1) CL2012002418A1 (OSRAM)
CO (1) CO6602134A2 (OSRAM)
CR (1) CR20120491A (OSRAM)
CY (2) CY1118046T1 (OSRAM)
DK (2) DK2542261T3 (OSRAM)
DO (1) DOP2012000232A (OSRAM)
EA (1) EA026375B1 (OSRAM)
ES (2) ES2593454T3 (OSRAM)
HR (2) HRP20161096T1 (OSRAM)
HU (1) HUE028960T2 (OSRAM)
IL (2) IL221418A (OSRAM)
JO (1) JO3188B1 (OSRAM)
LT (2) LT3025729T (OSRAM)
MA (1) MA34135B1 (OSRAM)
ME (1) ME02491B (OSRAM)
MX (1) MX340350B (OSRAM)
MY (1) MY159255A (OSRAM)
NZ (1) NZ601763A (OSRAM)
PE (1) PE20130040A1 (OSRAM)
PH (1) PH12012501743A1 (OSRAM)
PL (2) PL2542261T3 (OSRAM)
PT (2) PT2542261T (OSRAM)
RS (2) RS55133B1 (OSRAM)
SG (2) SG183316A1 (OSRAM)
SI (2) SI2542261T1 (OSRAM)
SM (2) SMT201800633T1 (OSRAM)
TW (1) TWI558409B (OSRAM)
UA (1) UA108227C2 (OSRAM)
UY (1) UY33258A (OSRAM)
WO (1) WO2011107480A1 (OSRAM)
ZA (1) ZA201206529B (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2506876B1 (en) * 2009-12-02 2016-10-12 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
EA031025B1 (ru) * 2012-12-21 2018-11-30 Сиэтл Дженетикс, Инк. Антитела против ntb-a и связанные с ними композиции и способы
CN103239713A (zh) * 2013-05-28 2013-08-14 东南大学 一种糖尿病肾病微炎症小鼠模型的建立方法
US9737505B2 (en) * 2014-04-29 2017-08-22 Glaxosmithkline Intellectual Property Development Limited Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline
GB201407506D0 (en) 2014-04-29 2014-06-11 Glaxosmithkline Ip Dev Ltd Novel compound
CN108136012B (zh) 2015-08-07 2022-10-04 伊麦吉纳博公司 靶向分子的抗原结合构建体
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
WO2019185502A1 (en) 2018-03-26 2019-10-03 Glaxosmithkline Intellectual Property Development Limited Antibodies comprising methionine sulfoxide at the ch2-ch3 interface
CN116925216B (zh) * 2022-04-11 2024-09-24 东莞市朋志生物科技有限公司 抗血清淀粉样蛋白a抗体、检测血清淀粉样蛋白a的试剂和试剂盒

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995005394A1 (en) * 1993-08-17 1995-02-23 Royal Postgraduate Medical School Therapeutic and diagnostic agents for amyloidosis
WO2009000926A1 (en) * 2007-06-27 2008-12-31 Pentraxin Therapeutics Limited Combinations of sap depleting agents and anti-sap antibodies
WO2009155962A1 (en) * 2008-06-27 2009-12-30 Pentraxin Therapeutics Limited Use

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
WO1994029347A1 (en) 1993-06-03 1994-12-22 Therapeutic Antibodies Inc. Antibody fragments in therapy
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5795737A (en) 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
CN1252075A (zh) 1997-02-07 2000-05-03 麦克公司 合成的hiv gag基因
DE69808017T2 (de) 1997-10-31 2003-04-30 F. Hoffmann-La Roche Ag, Basel D-Prolinderivate
GB9806530D0 (en) 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7504256B1 (en) 1999-10-19 2009-03-17 Kyowa Hakko Kogyo Co., Ltd. Process for producing polypeptide
JP2005538706A (ja) 2001-07-12 2005-12-22 ジェファーソン フーテ， スーパーヒト化抗体
CA2838062C (en) 2001-08-03 2015-12-22 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US6903129B2 (en) 2001-12-14 2005-06-07 Hoffman-La Roche Inc. D-proline prodrugs
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
EP3321282A1 (en) 2002-09-27 2018-05-16 Xencor, Inc. Optimized fc variants and methods for their generation
WO2004059318A2 (en) 2002-12-23 2004-07-15 William Marsh Rice University Methods of detecting the inhibition of fibrocyte formation and methods and compositions for enhancing fibrocyte formation
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
CA2525302A1 (en) 2003-05-12 2004-11-18 David Bundle Multivalent inhibitors of serum amyloid p component
JP2008512353A (ja) 2004-07-21 2008-04-24 グライコフィ， インコーポレイテッド 主にＧｌｃＮＡｃ２Ｍａｎ３ＧｌｃＮＡｃ２グリコフォームを含むイムノグロブリン

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995005394A1 (en) * 1993-08-17 1995-02-23 Royal Postgraduate Medical School Therapeutic and diagnostic agents for amyloidosis
WO2009000926A1 (en) * 2007-06-27 2008-12-31 Pentraxin Therapeutics Limited Combinations of sap depleting agents and anti-sap antibodies
WO2009155962A1 (en) * 2008-06-27 2009-12-30 Pentraxin Therapeutics Limited Use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JULIAN D. GILMORE, ET AL: "Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis", BRITISH JOURNAL OF HAEMATOLOGY, WILEY-BLACKWELL PUBLISHING LTD., GB, vol. 148, 1 January 2010 (2010-01-01), GB, pages 760 - 767, XP007918426, ISSN: 0007-1048, DOI: 10.1111/j.1365-2141.2009.08036.x *
KARL BODIN, ET AL: "Antibodies to human serum amyloid P component eliminate visceral amyloid deposits", NATURE, NATURE PUBLISHING GROUP, UNITED KINGDOM, vol. 468, 4 November 2010 (2010-11-04), United Kingdom, pages 93 - 97, XP007918427, ISSN: 0028-0836, DOI: 10.1038/nature09494 *
PEPYS M B ET AL: "Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis.", NATURE, NATURE PUBLISHING GROUP, UNITED KINGDOM, vol. 417, no. 6886, 1 January 2002 (2002-01-01), United Kingdom, pages 254 - 259, XP002219442, ISSN: 0028-0836, DOI: 10.1038/417254a *
SIMON E. KOLSTOE, ET AL: "Molecular dissection of Alzheimer�s disease neuropathology by depletion of serum amyloid P component", PROCEEDINGS NATIONAL ACADEMY OF SCIENCES PNAS, NATIONAL ACADEMY OF SCIENCES, US, vol. 106, no. 18, 5 May 2009 (2009-05-05), US, pages 7619 - 7623, XP007918428, ISSN: 0027-8424, DOI: 10.1073/pnas.0902640106 *

Also Published As

Publication number Publication date
HRP20161096T1 (hr) 2016-11-04
LT2542261T (lt) 2016-09-26
LT3025729T (lt) 2018-12-10
EP2542261A1 (en) 2013-01-09
CL2012002418A1 (es) 2013-03-08
SI2542261T1 (sl) 2016-11-30
AU2011223048C1 (en) 2018-06-21
HRP20181666T1 (hr) 2018-12-14
SMT201600337B (it) 2016-11-10
CN102858371A (zh) 2013-01-02
JO3188B1 (ar) 2018-03-08
TW201143789A (en) 2011-12-16
HK1173959A1 (zh) 2013-05-31
RS55133B1 (sr) 2016-12-30
CY1118046T1 (el) 2017-05-17
JP6236478B2 (ja) 2017-11-22
UA108227C2 (xx) 2015-04-10
DOP2012000232A (es) 2013-01-15
MX340350B (es) 2016-07-06
EP3025729B1 (en) 2018-09-12
SMT201800633T1 (it) 2019-01-11
ES2699078T3 (es) 2019-02-07
EP2542261B1 (en) 2016-07-06
JP2013521252A (ja) 2013-06-10
HUE028960T2 (en) 2017-01-30
ZA201206529B (en) 2018-12-19
IL221418A (en) 2017-03-30
WO2011107480A1 (en) 2011-09-09
KR101817265B1 (ko) 2018-01-10
ME02491B (me) 2017-02-20
DK2542261T3 (en) 2016-09-19
IL251031A0 (en) 2017-04-30
SG183316A1 (en) 2012-09-27
NZ601763A (en) 2014-08-29
CY1120803T1 (el) 2019-12-11
EP3025729A1 (en) 2016-06-01
MY159255A (en) 2016-12-30
UY33258A (es) 2011-09-30
ES2593454T3 (es) 2016-12-09
CA2789557A1 (en) 2011-09-09
PT3025729T (pt) 2018-11-30
PH12012501743A1 (en) 2012-11-12
IL251031A (en) 2017-11-30
BR112012021926A2 (pt) 2020-08-25
AU2011223048A1 (en) 2012-10-04
TWI558409B (zh) 2016-11-21
MA34135B1 (fr) 2013-04-03
DK3025729T3 (en) 2018-11-26
EA201290671A1 (ru) 2013-05-30
PT2542261T (pt) 2016-09-27
JP2016154535A (ja) 2016-09-01
AR080432A1 (es) 2012-04-11
KR20130027483A (ko) 2013-03-15
AU2011223048B2 (en) 2013-12-19
CN102858371B (zh) 2017-03-01
PL3025729T3 (pl) 2019-02-28
RS57708B1 (sr) 2018-12-31
PL2542261T3 (pl) 2016-12-30
SI3025729T1 (sl) 2018-11-30
PE20130040A1 (es) 2013-02-09
HK1223292A1 (en) 2017-07-28
CO6602134A2 (es) 2013-01-18
MX2012010129A (es) 2012-09-12
CR20120491A (es) 2013-02-20
SG10201500382SA (en) 2015-03-30
JP5922592B2 (ja) 2016-05-24
IL221418A0 (en) 2012-10-31

Similar Documents

Publication Publication Date Title
US20240124599A1 (en) Anti-bcma heavy chain-only antibodies
US20230060847A1 (en) Anti-bcma heavy chain-only antibodies
EA026375B1 (ru) Антигенсвязывающие белки, специфические в отношении сывороточного амилоидного компонента р
AU2008330125B2 (en) Wise binding antibodies and epitopes
JP6675739B2 (ja) 新規抗ｐａｄ４抗体
JP2022179611A (ja) 抗ｃｔｌａ４抗体及びその用途
JP5564049B2 (ja) 抗ｃｄ１４７抗体、方法及び使用
JP2021184731A (ja) Ｃｄ１２７に対する抗体
EP3753951A1 (en) Anti-b7-h4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
RS55571B1 (sr) Anti-c5a vezujuće grupe sa visokom blokirajućom aktivnosti
TW200914465A (en) Humanized antibodies to Aβ(20-42) globulomer and uses thereof
JP2022512043A (ja) 合理的に設計された新規なタンパク質組成物
MX2010012142A (es) Anticuerpos para receptor de productos finales de glucacion avanzada (rage) y usos de los mismos.
WO2011053707A1 (en) Antibodies to receptor for advanced glycation end products (rage) and uses thereof
AU2021202612B2 (en) Inhibition of platelet aggregation using anti-human GPVI antibodies
CN108289939A (zh) 新型抗人gpvi抗体及其用途
US9587015B2 (en) Anti-human CTGF antibody
WO2022136685A1 (en) Antibody compositions for treatment of corona virus infection
JP2025519056A (ja) Ｋｌｒｂ１結合剤及びその使用方法
CN115996951A (zh) 抗cd103抗体
TW201139667A (en) Amyloid-beta binding proteins
WO2024002145A1 (zh) 结合il-17a和il-17f的抗体分子及其应用
HK1173959B (en) Antigen binding proteins specific for serum amyloid p component

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU